Staidson Hongkong Investment Co. Ltd. (STS)

STS (SZSE: 300204) is an innovative biopharmaceutical company dedicated to research and development, production and sales of drugs. STS is a high-tech enterprise with a complete system of research and development, production and marketing. Founded in 2002, STS was listed on the Shenzhen Stock Exchange in 2011. STS is committed to research, development, production and sales of therapeutic drugs with unmet clinical needs, including protein drugs (including therapeutic monoclonal antibody drugs), gene therapy/cell therapy drugs and chemical drugs. *

	Start	2016-07-21 existent
	Group	Staidson (STS) (Group)
	Industry	finance
	Industry 2	LIFE SCIENCES

	City	n. a.
		Address record changed: 2016-07-21

Basic data	Employees	n. a.

		* Document for »About Section«: InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena.

		Record changed: 2022-12-22

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Staidson (STS) (Group)

[1] InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]